Roche caves on transparency issue; China reworks drug policies; GSK joins patent pool;

@FiercePharma: Allergan settles Botox case in OK. Article | Follow @FiercePharma

@EricPFierce: AstraZeneca manager accused of getting home makeover at the company's cost. Sunroom, new kitchen, bathroom fixtures. Story | Follow @EricPFierce

> Roche ($RHHBY) says it will set up an independent body that can grant access to trial data for researchers, similar to what GlaxoSmithKline ($GSK) is doing. Story

> GlaxoSmithKline will share intellectual property rights on children's HIV/AIDS drugs in a patent pool designed to make them more affordable in poor countries. Story

> China's State Food and Drug Administration says it is setting up new rules to speed up and improve the approval process for drugs there. Story

> Falling pharmaceutical production resulted in Singapore's industrial production falling 0.4% in January instead of the 5.2% increase anticipated. Article

Biotech News

 @FierceBiotech: From FierceVaccines.com: Is it too soon to quit on Nabi's nicotine vaccine? More | Follow @FierceBiotech

@JohnCFierce: Optimer shares spiking with CEO turned out and the board looking for a buyer. Release | Follow @JohnCFierce

@RyanMFierce: What Facebook and Google billionaires could do for overlooked biotech brains. Item | Follow @RyanMFierce

> Shionogi wins FDA approval on Osphena for painful sex. Story

> Vertex plots a race through PhIII for 'breakthrough' combo CF therapy. Report

> Jazz strikes up a $120M Concert Pharma collaboration on next-gen Xyrem. More

> Roche follows GSK in move to unlock its data vault on drugs. Article

Medical Device News

 @FierceMedDev: Work advances on early-detection ovarian cancer blood Dx. Story | Follow @FierceMedDev

 @MarkHFierce: J&J faces possible punitive damages in the first verdict regarding faulty vaginal mesh. Thousands of cases to come. Report | Follow @MarkHFierce

 @DamianFierce: The device industry is urging lawmakers to settle on a budget and, of course, repeal the device tax. Article | Follow @DamianFierce

> Quotient draws another $5M for transfusion Dx development. Story

> France's SpineGuard wins Russian nod for wireless spine surgery tool. Item

> Devicemakers: Excise tax, budget battle could cripple industry. Article

Drug Delivery News

@MichaelGFierce: Sanofi's Genzyme hits target with muscular dystrophy RNA drug in mice. Article | Follow @MichaelGFierce

> Ocular Therapeutix submits cataract-surgery sealant for FDA approval. Story

> Synthetic protein tricks immune system for drug delivery, device safety. News

> SHL ups Taiwanese auto injector production by $40M. More

And Finally... The owner and operator of an anti-aging clinic was convicted of selling human growth hormone, given more than two years in prison and ordered to cough up half a million dollars. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.